Carisbamate

FDA Approves XCOPRI® (cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.

Retrieved on: 
Thursday, November 21, 2019
Health, Medicine, Clinical medicine, RTT, Anticonvulsants, Epileptic seizure, Epilepsy, Food and Drug Administration, Syndromes, Carisbamate, Responsive neurostimulation device

The FDA approval of XCOPRI for the treatment of partial-onset seizures is a welcome option for the epilepsy community."

Key Points: 
  • The FDA approval of XCOPRI for the treatment of partial-onset seizures is a welcome option for the epilepsy community."
  • The approval also marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval.
  • XCOPRI was discovered and developed by SK Biopharmaceuticals and SK life science and is an FDA-approved anti-epileptic drug (AED) for the treatment of partial-onset seizures in adults.
  • SK life science, based in Paramus, New Jersey, is pursuing clinical development and the U.S. commercialization of XCOPRI.